The latter are targets of the following asthma drugs: anti-IL-5/IL-5R monoclonal antibodies (Mepolizumab, Benralizumab, Reslizumab), and anti-IL-4Rα monoclonal antibody (Dupilumab) (Fig. 3). Here, IL5 is linked to asthma.